Navigation Links
Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
Date:1/31/2011

eloma. We are committed to making carfilzomib available to these very ill patients as quickly as possible."

Carfilzomib was granted orphan drug designation by the FDA for the treatment of multiple myeloma in 2008.  Orphan drug designation is granted to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. Under the designation, the sponsor may be eligible for grant funding towards clinical trial costs, tax advantages, FDA user-fee benefits, and seven years of market exclusivity in the United States following drug approval by the FDA.

About the Carfilzomib Development Program

Carfilzomib is a selective, next generation proteasome inhibitor that has shown encouraging results in a broad clinical trial program in multiple myeloma.  

The carfilzomib development program includes a large, randomized international Phase 3 clinical trial, known as the ASPIRE trial, studying the combination of lenalidomide and low dose dexamethasone with or without carfilzomib in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial. A second Phase 3 clinical trial, called the FOCUS trial, is evaluating carfilzomib in patients with relapsed and refractory myeloma in Europe. Carfilzomib is also being evaluated in a broad investigator sponsored trial program including 1st line multiple myeloma, combination studies, lymphoma and other malignancies.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In the United States, more than 50,000 people are living with multiple myeloma and approximately 20,000 new cases are diagnosed ann
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Calif., Sept. 19, 2014  InterMune, Inc. (Nasdaq: ... a Memorandum of Understanding to settle the litigation in ... and Plan of Merger dated as of August 22, ... InterMune, Inc.  As one term of the Memorandum of ... set forth in the attached exhibit reflecting the amendment ...
(Date:9/19/2014)... September 18, 2014 Scientists at NYU Langone Medical ... the efficiency of the process for turning adult cells ... compounds, including vitamin C. Using the new technique in ... obtained from adult skin cells by more than 20-fold ... is efficient and reliable, and thus should generally accelerate ...
(Date:9/19/2014)... 19, 2014 Follow us ... to revolutionize the world has attracted diverse players ... small start-ups. The early years of nanotechnology development ... due to the high risks involved, which deterred ... for this evolving technology have been growing over ...
(Date:9/19/2014)... , September 19, 2014 ... technology, development of emerging drug systems and advanced Laboratory ... Dickinson and Company (NYSE: BDX ), Thermo ... Biosciences Inc. (NASDAQ: RGDO ), Sangamo Biosciences ... (NASDAQ: HOLX) Pressure BioSciences, Inc. (OTCQB: PBIO) ...
Breaking Biology Technology:InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 2InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 5InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 6InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 7InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 8InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 9InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 10InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 11InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 12InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 13InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 14InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 15InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 16InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 17InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 18InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 19NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7
... Elekta Neuromag(R),the world-leading equipment for non-invasive ... has been ordered by The,Nebraska Medical Center ... ), With a reputation for excellence, ... Center has earned J.D. Power and Associates,Hospital ...
... response to the,recent comments by certain plaintiff law firms ... (the "Company") (OTC,Bulletin Board: CCYG) asserts that the pending ... so in a court of law. To that end, ... LLP as its counsel and,will defend itself vigorously in ...
... Inc. (Nasdaq: CALP ) today announced that ... Mid Cap Growth Conference in Naples, Florida,will be ... EST. Kevin,Hrusovsky, President and CEO of Caliper, will ... live webcast can be accessed at, http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=CALP&item_id=17485 ,73. ...
Cached Biology Technology:Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center 2Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center 3CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases 2CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases 3
(Date:9/19/2014)... fairness did not evolve for the sake of fairness ... of continued cooperation, so say Frans de Waal, PhD, ... about inequity aversion (IA), which is defined as a ... in Science . , Their conclusion comes ... to address their hypothesis that it is the evolution ...
(Date:9/19/2014)... 2014 Nxt-ID, Inc. (Nasdaq: NXTD and ... the growing m-commerce market, updates the "Wocket in Your Pocket" celebrity ... and light middleweight weight classes, Vinny Pazienza (PAZ). ... Game of Thrones actor Ciaran Hinds and ... star Katey Sagal have been cast in Bleed ...
(Date:9/18/2014)... State University researchers have developed a unique method to ... cleanup in rural areas. , The first microbe-powered, ... and quick way to clean up waste from large ... pollution. , Professor Haluk Beyenal and graduate student ... Architecture discuss the system in the online edition of ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Researchers develop unique waste cleanup for rural areas 2
... laboratory mice that bear aggressive human breast cancers, UC ... growth of tumors -- without damage to surrounding healthy ... issue of the Journal of Nuclear Medicine. , "We ... mice. The next step will be clinical testing in ...
... of hearing have found an underlying molecular cause for ... deafness and the organization of liquid crystals, which are ... the inner ear, sound waves cause the basilar membrane ... trigger nerve impulses that are transmitted to the brain. ...
... in collaboration with colleagues from UC Berkeley and StrataGent ... novel pulsed microjet system engineered to deliver protein drugs ... deeper penetration injection systems cause. The research was published ... of Sciences. , The effort to create needle-free ...
Cached Biology News:UC Davis researchers use heated nanoprobes to destroy breast cancer cells in mice 2Scientists identify molecular cause for one form of deafness 2Researchers design pulsed mircrojet system to deliver protein drugs without pain or bruising 2
Porcine Coronary Artery Endothelial Cells (PCAEC) (>500,000 cells)...
Proliferin (N-14)...
Recognizes the ~115 kDa NMDA receptor NR1 subunit in rat cortex tissue extracts....
... Ligase catalyzes the formation of phosphodiester bonds ... DNAs with 3' hydroxyl and 5' phosphate ... optimizes ligation which can be performed in ... not substrates for this enzyme. A ...
Biology Products: